CCP 05-24-1993 - Laserfiche WebLink

Home Browse Search

. 1993 SESSiON WRAP-UP (t~tTi HEALTH CARE MINNESOTA CARE The 1992 MinnesotaCare Act charged the Minnesota Health Care Commission with the responsibility of creating a cost-containment plan which would "reduce the rate of heaith care spending by at least 10% per year for each of the next five years: This plan does that. saving $7.1 billion in the next five years. It combines expanding competition through ISNs, with setting limits on growth rates in and outside the ISN system. Intearated Service Networks (lSNs) - A plan All-Pavor System - The Health Commis- will be developed for implementing iSNs by sioner. in consuitation with the Commission, July 1,1994, The plan will be reviewed by the shall develop recommendations to design a Legislature and Governor. The plan must system to control spending growth outside address the following issues: the ISN system. The recommendations shall . medical malpractice liability be reported to the Legislature by January 1, . relation, rights and duties of ISNs to 1994, The system will be phased-In starting MCHA July 1, 1994, with full Implementation by July . 1,1996. . enrollee protection in the event of an ISN insolvency PUblic Health Goals - Public health goals will . risk and reinsurance be established by the Commissioner. Provid- ers shall report information on changes in . solvency requirements health outcomes related to those goals. ISNs are not mandatory, Doctors/hospitals Regional coordinating boards will assist. are not required to join ISNs, They may Gifts to Doctors - Gifts to doctors from drug choose to create an ISN, contract with one or manufacturers are prohibited if they value more ISNs. choose not to affiliate with any more than $50 in a calendar year. Education ISN, or service both ISN and non-ISN pa- materials or publications are exempt. tients. Generic Druas - Generic drugs shall be used ISNs may be organized as non-profits under in place of brand name labels when the doctor Chapter 317 A or as cooperatives under 30BA. does not require brand name, a pharmacist Commissioner shall conduct a srudy and make believes a generic has an equal, therapeutic recommendations on the issue of providing value, the generic is less expensive and the grants/loans to entities forming ISNs. patient chooses the generic. A few excep- tions apply for drugs used to prevent seizures Commissioner and Commission will develop and phenobarbital. methods to allocate and assess medical edu- cation and research costs. . II J